The vaccine known as Bexsero will be available to children in addition to two booster shots in an effort to combat Meningitis B.
The development of the vaccine, which has been lauded as a significant breakthrough in the medical field, is welcome news as it comes following twenty years of research and clinical trials.
Bexsero, which was has been tested on more than 8,000 people, is thought to provide 73% protection against the disease which is most common in children under the age of five.
Cases of the disease, which affects the spinal cord and the membranes surrounding the brain, will be reduced significantly following the introduction of the new vaccine.
While negotiations over costs has delayed the process, it is said that Bexsero is due to become available on the NHS in Autumn of this year.
